Hiroyuki Ushio, Seigo Ishibuchi, Kunitomo Adachi, Kouichi Oshita and Kenji Chiba Pages 292 - 296 ( 5 )
Through the optimization of the active metabolite 2 of the piperidine derivative 1, we discovered a potent new drug candidate for the treatment of RA, Y-320 that inhibits T cell activation induced by IL-15 and shows a therapeutic effect on collagen-induced arthritis in DBA/1J mice. Design and structure-activity relationships are described.
Y-320, IL-15, Phenylpyrazoleanilide, RA, CIA
Medicinal Chemistry Laboratory,Research division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.